

**In the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-102 (Canceled)

103. (Currently Amended) An isolated, enriched or purified immunogenic composition comprising:

one or more autologous target carcinoma or lymphoma cells which have been irradiated and treated in vitro wherein said target carcinoma or lymphoma cells express one or more primary or costimulatory T cell activation molecules at a level higher than the amount of primary or costimulatory T cell activation molecules expressed from carcinoma or lymphoma cells without treatment in a patient mammal;

one or more antibodies ~~wherein said antibodies further bind to an antigenic binding site bound to a gp55, gp95 or gp210 antigen~~ on the surface of said one or more target carcinoma or lymphoma cells, ~~wherein said gp55 antigen binds to an antibody produced by the hybridoma cell line CCTCC-C200305, said gp95 antigen binds to an antibody produced by the hybridoma cell line CCTCC-C200306, and said gp210 antigen binds to an antibody produced by the hybridoma cell line CCTCC-C200307, respectively;~~

~~one or more primary or costimulatory T cell activation molecules on the surface of T cells in said patient mammal; and~~

a bridge molecule bispecific antibody that binds to said gp55, gp95 or gp210 binding antibody antibodies and said primary or costimulatory T cell activation molecules on the surface of T cells of said patient mammal.

Claims 104-106 (Canceled)

107. (Currently Amended) The composition of claim 103, wherein said one or more hepatocellular carcinoma, lymphoma or colorectal carcinoma cells target carcinoma cells comprise one or more hepatocellular carcinoma cells.

Claims 108 and 109 (Withdrawn)

110. (Currently Amended) The composition of claim 103, wherein said one or more primary or costimulatory T cell activation molecules on the surface of T cells are CD28 or 4-1BB molecules comprise one or more CD28 molecules.

111. (Currently Amended) The composition of claim 103, wherein said one or more primary or costimulatory T cell activation molecules on the surface of T cells are CD28 or 4-1BB molecule comprise one or more 4-1BB molecules.

112. (Currently Amended) The composition of claim 103, wherein said one or more hepatocellular carcinoma or colorectal carcinoma target carcinoma or lymphoma cells express said one or more CD28 or 4-1BB primary or costimulatory T cell activation molecules at a level

50% higher than the amount that said one or more CD28 or 4-1BB primary or costimulatory T cell activation molecules are expressed from hepatocellular carcinoma, lymphoma or colorectal carcinoma target carcinoma or lymphoma cells in a patient mammal.

113. (Currently Amended) The composition of claim 103, wherein said hepatocellular carcinoma or colorectal carcinoma cell expresses one or more target carcinoma or lymphoma cells express said one or more CD28 or 4-1BB primary or costimulatory T cell activation molecules at a level 2 fold higher than the amount that said one or more CD28 or 4-1BB primary or costimulatory T cell activation molecules are expressed from hepatocellular carcinoma or colorectal carcinoma target carcinoma or lymphoma cells in a patient mammal.

114. (Currently Amended) The composition of claim 103, wherein hepatocellular carcinoma, lymphoma or colorectal carcinoma cell expresses said one or more target carcinoma or lymphoma cells express one or more CD28 or 4-1BB said primary or costimulatory T cell activation molecules at a level 10 fold higher than the amount that said one or more CD28 or 4-1BB primary or costimulatory T cell activation molecules are expressed from hepatocellular carcinoma, lymphoma or colorectal carcinoma target carcinoma or lymphoma cells in a patient mammal.

115. (Previously Added) The composition of claim 103, wherein said patient mammal is a human.

Claims 116 and 117 (Withdrawn)

118. (Currently Amended) The composition of claim 103, wherein the one or more target ~~hepatocellular carcinoma, or lymphoma or colorectal carcinoma~~ cells are treated with IFN- $\gamma$  and TNF- $\alpha$ .

119. (Currently Amended) The composition of claim 103, wherein said bispecific antibody is a bispecific ~~or multispecific~~ monoclonal antibody.

Claim 120 (Canceled)

121. (Currently Amended) The composition of claim 103, wherein substantially all of said gp55, gp95 or gp210 binding antibodies are attached to said ~~hepatocellular carcinoma, or lymphoma or colorectal carcinoma~~ cells.

122. (Currently Amended) The composition of claim 103, wherein over 80% of said gp55, gp95 or gp210 binding antibodies are attached to said ~~hepatocellular carcinoma, or lymphoma or colorectal carcinoma~~ cells.

123. (Currently Amended) The composition of claim 103, wherein over 90% of said gp55, gp95 or gp210 binding antibodies are attached to said ~~hepatocellular carcinoma, or lymphoma or colorectal carcinoma~~ cells.

124. (Currently Amended) The composition of claim 103, wherein over 95% of said gp55, gp95 or gp210 binding antibodies are attached to said hepatocellular carcinoma, or lymphoma or colorectal carcinoma cells.

Claim 125 (Canceled)

126. (Currently Amended) The composition of claim 103, wherein a pharmaceutically effective amount of said gp55, gp95 or gp210 binding antibodies are bound to hepatocellular carcinoma, or lymphoma or colorectal carcinoma cells.

127. (Previously Added) The composition of claim 103, further comprising a pharmaceutically acceptable carrier or excipient.

128. (Currently Amended) The composition of claim 103, wherein at least one of said hepatocellular carcinoma, or lymphoma or colorectal carcinoma cells has attached thereto a plurality of said gp55, gp95 or gp210 binding antibodies.

129. (Currently Amended) The composition of claim 103, wherein said gp55, gp95 or gp210 binding antibodies comprise two or more antigen binding sites for one or more the gp55 antigens antigen on the surface of said one or more target hepatocellular carcinoma, or lymphoma or colorectal carcinoma cells.

130. (Currently Amended) The composition of claim 103, wherein said antibodies comprise bispecific antibody comprises two or more binding sites for said one or more CD28 or 4-1BB molecules on the surface of T cells in said patient mammal.

131. (Currently Amended) The composition of claim 103, wherein said composition comprises two or more gp55, gp95 or gp210 binding antibodies ~~comprising one or more antigen binding sites for one or more gp55 antigens on the surface of said one or more target hepatocellular carcinoma, lymphoma or colorectal carcinoma cells.~~

132. (Currently Amended) The composition of claim 103, wherein said composition comprises two or more bispecific antibodies each comprising a binding site for a different one of said CD28 or 4-1BB molecules.

133. (Currently Amended) The composition of claim 103, wherein said composition comprises two or more gp55, gp95 or gp210 binding antibodies each attached to a different antigen.

134. (Previously Added) The composition of claim 103, further comprising a pharmaceutically effective amount of IFN- $\gamma$ , TNF- $\alpha$ , or both.

135. (Currently Amended) The composition of claim 103, wherein said hepatocellular carcinoma, or lymphoma or colorectal carcinoma cells are treated with 10-100 U of IFN- $\gamma$  and 10-100 U of TNF- $\alpha$ .

136. (Currently Amended) The composition of claim 103, wherein said hepatocellular carcinoma, or lymphoma or colorectal carcinoma cells are treated with 100 U of IFN- $\gamma$  and 50 U of TNF- $\alpha$ .

137. (Previously Added) The composition of claim 107, wherein said hepatocellular carcinoma cells are hepa 1-6 cells.

Claims 138 and 139 (Withdrawn)

140. (Currently Amended) The composition of claim 103, wherein said target carcinoma cells further comprise are hepatocellular carcinoma or colorectal carcinoma cells.

141. (Currently Amended) The composition of claim 103, wherein said gp55, gp95 or gp210 binding antibodies further comprise one or more binding sites for antigen gp55, gp95 or gp210.

142. (Previously Added) The composition of claim 103, wherein said primary or costimulatory T cell activation molecules bind to CD28 or 4-1BB.

Claim 143 (Canceled)

144. (New) The composition of claim 103, wherein said primary T cell activation molecule is a MHC class I or a MHC class II molecule.

145. (New) The composition of claim 103, wherein said costimulatory T cell activation molecule is selected from the group consisting of ICAM-1, ICAM-2, ICAM-3, LFA-1, LFA-2, VLA-1, VCAM-1, 4-1-BB L, B7-1 and B7-2.